STERIS plc · NYSE (us_market)
Healthcare · Medical Devices · United States
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-02-22$236.03 RISE2024-04-16$199.01 PEAK2024-05-14$236.00 82d | -15.7% 54d | Missed | Missed | — | — | +18.6% 28d | Missed |
DROP2023-07-25$233.02 RISE2023-11-29$197.44 PEAK2024-02-22$236.03 212d | -15.3% 127d | Missed | Missed | — | — | +19.5% 85d | Missed |
DROP2023-02-02$220.86 RISE2023-04-25$181.84 PEAK2023-07-21$232.09 169d | -17.7% 82d | Missed | Missed | — | — | +27.6% 87d | Missed |
DROP2023-02-02$220.86 RISE2023-03-15$176.39 PEAK2023-05-12$210.85 99d | -20.1% 41d | Missed | Missed | — | — | +19.5% 58d | Missed |
DROP2022-07-29$225.65 RISE2022-11-09$160.98 PEAK2023-02-02$220.86 188d | -28.7% 103d | Missed | Missed | — | — | +37.2% 85d | Missed |
DROP2022-05-27$235.00 RISE2022-09-27$160.72 PEAK2022-12-13$199.08 200d | -31.6% 123d | Missed | Missed | — | — | +23.9% 77d | Missed |
DROP2022-04-20$252.92 RISE2022-06-17$192.78 PEAK2022-07-29$225.65 100d | -23.8% 58d | Missed | Missed | — | — | +17.1% 42d | Missed |
DROP2021-01-08$202.81 RISE2021-03-04$171.20 PEAK2021-04-26$216.47 108d | -15.6% 55d | Missed | Missed | — | — | +26.4% 53d | Missed |
DROP2020-02-14$168.51 RISE2020-03-23$107.76 PEAK2020-05-29$165.89 105d | -36.1% 38d | Missed | Missed | — | — | +53.9% 67d | Missed |
STERIS has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
STERIS has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.
STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.
Generation IM Q1 2026 13F: portfolio drops to $11.16B; top holdings MSFT, AMZN & GOOGL; big buys/sells and new picks.
STERIS delivered Q1 results that met Wall Street’s revenue expectations, with the market reacting positively to the company’s performance. Management pointed to steady procedure volume growth in the U.S. and continued expansion in its Healthcare and Life Sciences segments as key drivers. CEO Dan Carestio cited strong service revenue, improved consumables growth, and a stabilizing capital equipment business, while also acknowledging external pressures such as inflation and tariffs. Notably, sever
STERIS delivered Q1 results that met Wall Street’s revenue expectations, with the market reacting positively to the company’s performance. Management pointed to steady procedure volume growth in the U.S. and continued expansion in its Healthcare and Life Sciences segments as key drivers. CEO Dan Carestio cited strong service revenue, improved consumables growth, and a stabilizing capital equipment business, while also acknowledging external pressures such as inflation and tariffs. Notably, sever
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STERIS (NYSE:STE) and the best and worst performers in the surgical equipment & consumables - diversified industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STERIS (NYSE:STE) and the best and worst performers in the surgical equipment & consumables - diversified industry.
Medical equipment and services company Steris (NYSE:STE). met Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.3% year on year to $1.59 billion. Its non-GAAP profit of $2.83 per share was 0.7% below analysts’ consensus estimates.
Medical equipment and services company Steris (NYSE:STE). met Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.3% year on year to $1.59 billion. Its non-GAAP profit of $2.83 per share was 0.7% below analysts’ consensus estimates.
STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing gains, while also outlining expectations for mid- to high-single-digit growth in fiscal 2027. Senior Vice P
STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing gains, while also outlining expectations for mid- to high-single-digit growth in fiscal 2027. Senior Vice P
Recent share performance and business scale STERIS (STE) has drawn investor attention after a period in which the stock declined about 6% over the past month and roughly 14% over the past 3 months, prompting closer review of its fundamentals. The company reports annual revenue of US$5.94b and net income of US$782.3m, with operations spanning Healthcare, Applied Sterilization Technologies and Life Sciences, and a market value of about US$20.68b. See our latest analysis for STERIS. At a share...
Recent share performance and business scale STERIS (STE) has drawn investor attention after a period in which the stock declined about 6% over the past month and roughly 14% over the past 3 months, prompting closer review of its fundamentals. The company reports annual revenue of US$5.94b and net income of US$782.3m, with operations spanning Healthcare, Applied Sterilization Technologies and Life Sciences, and a market value of about US$20.68b. See our latest analysis for STERIS. At a share...
Keybanc analyst Brett Fishbin maintains Steris (NYSE:STE) with a Overweight and lowers the price target from $291 to $269.
Medical equipment and services company Steris (NYSE:STE). will be reporting results this Monday after the bell. Here’s what you need to know.
Medical equipment and services company Steris (NYSE:STE). will be reporting results this Monday after the bell. Here’s what you need to know.
Steris PLC (STE) reports robust revenue growth and outlines strategic initiatives for fiscal 2027 amidst inflationary pressures and supply chain challenges.
Steris PLC (STE) reports robust revenue growth and outlines strategic initiatives for fiscal 2027 amidst inflationary pressures and supply chain challenges.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| STE | -0.78% | -14.14% | -16.09% | -13.25% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.75% | -8.43% | -12.65% | -25.93% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 4.99M | $1.10B | 0.04% | Added+8.2% | 2026-03-31 |
| Wellington | fundamental | 2.87M | $635.39M | 0.12% | Added+74.8% | 2026-03-31 |
| TwoSigma | quant | 479.1K | $105.95M | 0.09% | Added+465.7% | 2026-03-31 |
| DEShaw | quant | 176.2K | $38.95M | 0.02% | Added+337.2% | 2026-03-31 |
| FidelityFMR | fundamental | 56.9K | $12.59M | 0.00% | Trimmed-34.2% | 2026-03-31 |
| Citadel | multi-strat | 32.9K | $7.28M | 0.01% | Trimmed-8.0% | 2026-03-31 |
| Bridgewater | macro | 11.1K | $2.46M | 0.01% | Added+231.3% | 2026-03-31 |
| TRowePrice | fundamental | 1.76M | $389.88K | 0.05% | Added+410.3% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-06 | FELDMANN CYNTHIA L | Director | M Option exercise(deriv) | 3,098 | — | +$0 |
| 2026-03-06 | FELDMANN CYNTHIA L | Director | S Open-market sale | 3,098 | $237.21 | −$734.9K |
| 2026-03-06 | FELDMANN CYNTHIA L | Director | M Option exercise | 3,098 | $152.32 | +$471.9K |
| 2026-01-06 | McGowan Lindsey | VP, Chf. Comp. & Quality Offc. | A Grant / award | 798 | — | +$0 |
| 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | M Option exercise(deriv) | 2,136 | — | +$0 |
| 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | M Option exercise(deriv) | 2,872 | — | +$0 |
| 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | S Open-market sale | 2,136 | $262.00 | −$559.6K |
| 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | M Option exercise | 2,136 | $147.05 | +$314.1K |
| 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | S Open-market sale | 2,872 | $262.00 | −$752.5K |
| 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | M Option exercise | 2,872 | $114.22 | +$328.0K |
| 2025-11-20 | Tamaro Renato | V.P. & Corporate Treasurer | M Option exercise(deriv) | 3,536 | — | +$0 |
| 2025-11-20 | Tamaro Renato | V.P. & Corporate Treasurer | S Open-market sale | 1,500 | $257.76 | −$386.6K |
| 2025-11-20 | Tamaro Renato | V.P. & Corporate Treasurer | S Open-market sale | 212 | $258.03 | −$54.7K |
| 2025-11-20 | Tamaro Renato | V.P. & Corporate Treasurer | S Open-market sale | 3,324 | $257.43 | −$855.7K |
| 2025-11-20 | Tamaro Renato | V.P. & Corporate Treasurer | M Option exercise | 3,536 | $182.22 | +$644.3K |
| 2025-11-13 | Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | M Option exercise(deriv) | 15,000 | — | +$0 |
| 2025-11-13 | Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | S Open-market sale | 15,000 | $265.14 | −$3.98M |
| 2025-11-13 | Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | M Option exercise | 15,000 | $69.72 | +$1.05M |
| 2025-10-08 | Carestio Daniel A | President and CEO | S Open-market sale | 159 | $241.82 | −$38.4K |
| 2025-10-03 | Carestio Daniel A | President and CEO | F Tax withholding | 130 | — | +$0 |
| 2025-10-03 | Burton Karen L | Sr. Vice Pres., CFO | A Grant / award(deriv) | 8,356 | — | +$0 |
| 2025-10-03 | Burton Karen L | Sr. Vice Pres., CFO | A Grant / award | 2,349 | — | +$0 |
| 2025-10-03 | Burton Karen L | Sr. Vice Pres., CFO | F Tax withholding | 39 | — | +$0 |
| 2025-10-03 | Fraser Mary Clare | SVP & Chief HRO | F Tax withholding | 207 | — | +$0 |
| 2025-10-03 | Madsen Julia | Sr. VP and GM, Life Sciences | F Tax withholding | 52 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 2.50 | — | — |
| 2026-05-11 | 2.85 | 2.83 | -0.65% |
| 2026-02-04 | 2.53 | 2.53 | -0.10% |
| 2025-11-05 | 2.35 | 2.47 | +5.05% |
| 2025-08-06 | 2.26 | 2.34 | +3.37% |
| 2025-05-14 | 2.60 | 2.74 | +5.44% |
| 2025-02-05 | 2.32 | 2.32 | -0.06% |
| 2024-11-06 | 2.13 | 2.14 | +0.40% |
| 2024-08-06 | 1.98 | 2.03 | +2.67% |
| 2024-05-08 | 2.41 | 2.58 | +7.14% |
| 2024-02-07 | 2.17 | 2.22 | +2.37% |
| 2023-11-07 | 2.00 | 2.07 | +3.10% |
| 2023-08-01 | 1.86 | 2.00 | +7.53% |
| 2023-05-10 | 2.15 | 2.30 | +7.06% |
| 2023-02-08 | 2.19 | 2.02 | -7.90% |
| 2022-11-09 | 1.98 | 1.99 | +0.34% |